• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Appendix E: Development of Costs for the process for the review of Abbreviated Applications For Generic New Animal Drugs

Back to Table of Contents: FY2010 AGDUFA Financial Report 

General Methodology
 
The costs associated with the process for the review of abbreviated applications for generic new animal drugs are based on obligations recorded within FDA’s CVM, ORA, and Office of the Commissioner (OC). These organizations correspond to the cost categories presented as follows:

Cost Category
 FDA Organization
Costs for the Review of Abbreviated ANADAs, Supplemental Animal Generic Applications and Investigational Submissions
CVM
Costs for Field Pre-approval Inspection and Investigation
 
ORA
Costs for Agency General and Administrative Activities
OC

 
The costs were accumulated using time reporting systems in CVM and ORA, and were extrapolated for OC. Using the definitions of costs and activities included in the process for the review of abbreviated applications in the AGDUFA, as expanded in the discussion in Appendix D, the cost categories within each organization listed above were identified as parts of the abbreviated review process.
 
Center Costs
 
Costs are accumulated for CVM in FDA’s financial system in cost centers corresponding to the organizational components at the office level within CVM. Most CVM components involved in the generic new animal drug review process perform a mixture of activities—some included in the definition of the process for the review of abbreviated applications for generic new animal drugs, and some not included (see Appendix D). The activities involved in the process for the review of abbreviated applications for generic new animal drugs are categorized into three areas:  1) direct process activities, such as submission specific work; 2) indirect process and support activities, such as standard operating procedures and application review support; and 3) center-wide support activities. CVM’s ATR System supports the allocations for all three areas.
 
CVM’s ATR
 
CVM developed and implemented a total time reporting system as part of a multi-year Activity Based Costing initiative. The ATR has a robust Activity Dictionary developed by CVM employees, describing the work “activities” of the Center employees. The system was implemented center-wide in October 2003. All CVM employees report their time in ATR.
 
Using the Activity Dictionary in conjunction with the definition of the process for the review of abbreviated applications for generic new animal drugs in AGDUFA, CVM was able to attribute activity time reported by its employees to direct and indirect process and support activities as distinguished from non-process activities.  These activity definitions are consistent with the allowable costs for the process of the review of abbreviated applications for generic new animal drugs as detailed in Appendix D.
 
Agency-Wide Expenses
 
A number of agency-wide expenses are paid from the central accounts rather than from funds allocated to a specific center. These costs include rent for facilities that house CVM staff, telecommunications and utility costs, some computer equipment and support costs, facilities repair and maintenance costs, part of extramural and service contract costs, and costs of the Office of Shared Services which supports all FDA programs and activities. For these agency-wide costs that are chargeable to the center, we assumed that a percentage of them are chargeable to the process for the review of abbreviated applications for generic new animal drugs. That percentage was the amount of time reported for allowable activities (direct and indirect) in the center, as a percentage of total time reported for all center direct and indirect activities.
 
In support of the previous Administrations Management Agenda and Goal of “One-HHS”, FDA was requested to consolidate its administrative functions (including facilities, procurement, finance, equal employment opportunities, and information technology services) to carry out more efficient realignment of the resources which would provide high quality administrative services from a single organization. FDA created an Office of Shared Services in FY 2004. It combined the support responsibilities and resources previously located both in the centers and in OC, and ensured effective and efficient services in a competitive market environment. In this report resources expended by the Office of Shared Services in supporting the generic new animal drug review process are reported as if they were incurred in CVM, ORA, or OC.
 
Field Inspection and Investigation Costs
 
ORA incurs all field inspection, investigation, and laboratory analyses costs. ORA costs are incurred in both district offices (the "field") and headquarters offices. Since FY 2000, ORA tracks the accumulated costs through a system called FACTS. FACTS is a time and activity tracking system that captures time spent in a variety of categories, including pre-approval inspections of manufacturing facilities, investigations of clinical studies, and analytical testing of samples, which are all part of the review process for generic animal drug applications.
 
Total direct hours reported in FACTS are used to calculate the total number of staff-years required by ORA to perform these activities. In addition to the direct time, an allocation of support time is also included to represent the work done by the ORA administrative and management personnel. The agency, then, multiplies the total number of staff-years used in the process for the review of animal generic drug applications by the average salary cost in ORA to arrive at ORA salary costs for work that is a part of the process for the review of abbreviated applications for generic new animal drugs as defined in AGDUFA. The final step is to allocate ORA obligations for operations and rent to the animal generic drug review process based upon the ratio of user fee related staff-years to total ORA staff-years. The following table summarizes the calculation of ORA costs for the review of abbreviated applications for generic new animal drugs for FY 2010.
 
Table 11
Office of Regulatory Affairs Costs of the Review Process for Abbreviated Applications for Generic New Animal Drugs
As of September 30, 2010
 
Cost Component
FY 2009
FY 2010
Staff Years Utilized
3
2
ORA Average Salary and Benefits
$107,401
$108,065
Salary and Benefits
(Staff Years times ORA Average Salary and Benefits)
$322,203
$216,130
Operating and Other Costs
$243,774
$187,015
Grand Total
 (salary/benefits and operating/other costs)
$565,977
$403,145
 
Agency General and Administrative Costs
 
The agency general and administrative costs are incurred in the FDA's OC. At the end of
FY 2010, OC was comprised of the following offices:
 
  • Immediate Office of the Commissioner
  • Office of the Chief Counsel
  • Office of the Chief of Staff
  • Office of the Administrative Law Judge
  • Office of Equal Employment Opportunity and Diversity Management
  • Office of International Programs
  • Office of Administration
  • Office of Policy, Planning and Budget
  • Office of Special Medical Programs
  • Office of Legislation
  • Office of the Counselor to the Commissioner
  • Office of Women’s Health
  • Office of Foods
  • Office of the Chief Scientist
  • Office of International Programs
  • Office of External Affairs
 
The OC costs applicable to the process for the review of generic new animal drugs were calculated using a method prescribed by the Division of Cost Determination Management, Office of Finance, Office of the Secretary, Department of Health and Human Services. The method uses the percentage derived by dividing total OC costs by the total FDA salary expenses (excluding benefits) after subtracting the salary expense (excluding benefits) from OC.  That percentage is then multiplied by the sum of salaries (excluding benefits) applicable to the process for the review of abbreviated applications for generic new animal drugs in CVM and ORA to derive the applicable general and administrative costs.
 
Using this methodology, FDA dedicated $895,277 in general and administrative costs to the animal generic drug review process in FY 2010. The costs are total costs obligated from appropriations and user fees. FDA strives to maintain a low overhead cost for the review process of the abbreviated applications for generic new animal drugs. General and administrative costs are approximately 8 percent of FY 2010 generic new animal drug review process costs.